Please enable JavaScript to continue using this application.

Compare $RNAC vs $WHWK | Chartloom

Compare

$RNAC vs $WHWK

Cartesian Therapeutics Inc · Whitehawk Therapeutics Inc

RNAC

Cartesian Therapeutics Inc

WHWK

Whitehawk Therapeutics Inc

Compare $RNAC vs $WHWK

Comparing Cartesian Therapeutics Inc and Whitehawk Therapeutics Inc

RNACCartesian Therapeutics Inc

WHWKWhitehawk Therapeutics Inc

RNACCartesian Therapeutics Inc

Market cap

$207M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

473.62x

Rev growth (TTM)

-20.7%

YTD performance

4.4%

52W performance

-31.0%

FCF yield

-37.9%

WHWKWhitehawk Therapeutics Inc

Market cap

$189M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

44.3%

52W performance

65.3%

FCF yield

-36.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RNAC

WHWK

Detailed metrics comparison

RNAC

Cartesian Therapeutics Inc

WHWK

Whitehawk Therapeutics Inc

Market Cap

RNAC$207M

WHWK$189M

Enterprise Value

RNAC$113M

WHWK$104M

Price

RNAC$7.06

WHWK$3.52

P/E Ratio

RNACN/A

WHWKN/A

P/S Ratio

RNAC140.34x

WHWK7.56x

EV/Sales

RNAC76.18x

WHWK0.00x

EV/EBITDA

RNAC0.00x

WHWK0.00x

P/B Ratio

RNAC296.12x

WHWK1.15x

P/FCF Ratio

RNACN/A

WHWKN/A

EV/FCF

RNAC-1.43x

WHWK-1.50x

PEG Ratio

RNACN/A

WHWKN/A

Forward P/E (NTM)

RNACN/A

WHWKN/A

Forward P/S (NTM)

RNAC473.62x

WHWKN/A

Revenue (TTM)

RNAC$1M

WHWK$0

Revenue Growth (YoY)

RNAC-20.7%

WHWK-100.0%

Forward Rev Growth

RNAC-14.0%

WHWK167.6%

Gross Margin (TTM)

RNAC0.0%

WHWK88.7%

Operating Margin (TTM)

RNAC0.0%

WHWK87.4%

EBITDA Margin (TTM)

RNAC-6503.1%

WHWK0.0%

Net Margin (TTM)

RNAC-10422.5%

WHWK99.4%

FCF Margin (TTM)

RNAC-5322.4%

WHWKN/A

Net Income (TTM)

RNAC$-154M

WHWK$-80M

FCF (TTM)

RNAC$-79M

WHWK$-69M

EPS (TTM)

RNAC-$5.16

WHWK-$0.96

ROE (TTM)

RNAC-321582.0%

WHWK-5389.0%

ROA (TTM)

RNAC-4761.0%

WHWK-4997.0%

ROIC (TTM)

RNAC-321582.0%

WHWK-5389.0%

Cash

RNAC$148M

WHWK$85M

Debt

RNAC$53M

WHWK$0

Net Cash/Debt

RNAC$95M

WHWK$85M

Current Ratio (TTM)

RNAC7.48x

WHWK17.38x

Quick Ratio (TTM)

RNAC7.19x

WHWK17.16x

Debt/Equity (TTM)

RNAC0.28x

WHWK0.00x

Debt/Assets (TTM)

RNAC0.0%

WHWK0.0%

Interest Coverage (TTM)

RNACN/A

WHWKN/A

Net Debt/EBITDA (TTM)

RNAC0.00x

WHWK0.00x

Beta

RNAC0.74

WHWK0.99

52W Performance

RNAC-31.0%

WHWK65.3%

YTD Performance

RNAC4.4%

WHWK44.3%

% from 52W High

RNAC-35.9%

WHWK-35.9%

% from 52W Low

RNAC26.0%

WHWK88.2%

Asset Turnover (TTM)

RNAC0.01x

WHWK0.23x

FCF Yield (TTM)

RNAC-37.9%

WHWK-36.6%

Earnings Yield (TTM)

RNAC-74.3%

WHWK-42.2%

Dividend Yield (TTM)

RNACN/A

WHWKN/A

Rule of 40

RNAC-5,343.1

WHWK-100.0

EV/GP/RG

RNACN/A

WHWKN/A

Ticker research

View RNAC research View WHWK research

Metric	RNAC Cartesian Therapeutics Inc	WHWK Whitehawk Therapeutics Inc
Market & Valuation
Market Cap	$207M	$189M
Enterprise Value	$113M	$104M
Price	$7.06	$3.52
P/E Ratio	N/A	N/A
P/S Ratio	140.34x	7.56x
EV/Sales	76.18x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	296.12x	1.15x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.43x	-1.50x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	473.62x	N/A
Revenue & Growth
Revenue (TTM)	$1M	$0
Revenue Growth (YoY)	-20.7%	-100.0%
Forward Rev Growth	-14.0%	167.6%
Profitability
Gross Margin (TTM)	0.0%	88.7%
Operating Margin (TTM)	0.0%	87.4%
EBITDA Margin (TTM)	-6503.1%	0.0%
Net Margin (TTM)	-10422.5%	99.4%
FCF Margin (TTM)	-5322.4%	N/A
Net Income (TTM)	$-154M	$-80M
FCF (TTM)	$-79M	$-69M
EPS (TTM)	-$5.16	-$0.96
ROE (TTM)	-321582.0%	-5389.0%
ROA (TTM)	-4761.0%	-4997.0%
ROIC (TTM)	-321582.0%	-5389.0%
Financial Health
Cash	$148M	$85M
Debt	$53M	$0
Net Cash/Debt	$95M	$85M
Current Ratio (TTM)	7.48x	17.38x
Quick Ratio (TTM)	7.19x	17.16x
Debt/Equity (TTM)	0.28x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.74	0.99
52W Performance	-31.0%	65.3%
YTD Performance	4.4%	44.3%
% from 52W High	-35.9%	-35.9%
% from 52W Low	26.0%	88.2%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.23x
FCF Yield (TTM)	-37.9%	-36.6%
Earnings Yield (TTM)	-74.3%	-42.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-5,343.1	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View RNAC research	View WHWK research

Valuation

P/S Ratio

WHWK

7.56x

RNAC

140.34x

EV/FCF

WHWK

-1.50x

RNAC

-1.43x

Growth & revenue

Revenue Growth TTM

RNAC

-20.7%

WHWK

-100.0%

Forward Revenue Growth

WHWK

167.6%

RNAC

-14.0%

Profitability & performance

Gross Margin

WHWK

88.7%

RNAC

0.0%

ROE

WHWK

-5389.0%

RNAC

-321582.0%

FCF Yield %

WHWK

-36.6%

RNAC

-37.9%

52-Week Performance

WHWK

65.3%

RNAC

-31.0%

Detailed metrics comparison

RNAC

Cartesian Therapeutics Inc

WHWK

Whitehawk Therapeutics Inc

Market Cap

RNAC$207M

WHWK$189M

Enterprise Value

RNAC$113M

WHWK$104M

Price

RNAC$7.06

WHWK$3.52

P/E Ratio

RNACN/A

WHWKN/A

P/S Ratio

RNAC140.34x

WHWK7.56x

EV/Sales

RNAC76.18x

WHWK0.00x

EV/EBITDA

RNAC0.00x

WHWK0.00x

P/B Ratio

RNAC296.12x

WHWK1.15x

P/FCF Ratio

RNACN/A

WHWKN/A

EV/FCF

RNAC-1.43x

WHWK-1.50x

PEG Ratio

RNACN/A

WHWKN/A

Forward P/E (NTM)

RNACN/A

WHWKN/A

Forward P/S (NTM)

RNAC473.62x

WHWKN/A

Revenue (TTM)

RNAC$1M

WHWK$0

Revenue Growth (YoY)

RNAC-20.7%

WHWK-100.0%

Forward Rev Growth

RNAC-14.0%

WHWK167.6%

Gross Margin (TTM)

RNAC0.0%

WHWK88.7%

Operating Margin (TTM)

RNAC0.0%

WHWK87.4%

EBITDA Margin (TTM)

RNAC-6503.1%

WHWK0.0%

Net Margin (TTM)

RNAC-10422.5%

WHWK99.4%

FCF Margin (TTM)

RNAC-5322.4%

WHWKN/A

Net Income (TTM)

RNAC$-154M

WHWK$-80M

FCF (TTM)

RNAC$-79M

WHWK$-69M

EPS (TTM)

RNAC-$5.16

WHWK-$0.96

ROE (TTM)

RNAC-321582.0%

WHWK-5389.0%

ROA (TTM)

RNAC-4761.0%

WHWK-4997.0%

ROIC (TTM)

RNAC-321582.0%

WHWK-5389.0%

Cash

RNAC$148M

WHWK$85M

Debt

RNAC$53M

WHWK$0

Net Cash/Debt

RNAC$95M

WHWK$85M

Current Ratio (TTM)

RNAC7.48x

WHWK17.38x

Quick Ratio (TTM)

RNAC7.19x

WHWK17.16x

Debt/Equity (TTM)

RNAC0.28x

WHWK0.00x

Debt/Assets (TTM)

RNAC0.0%

WHWK0.0%

Interest Coverage (TTM)

RNACN/A

WHWKN/A

Net Debt/EBITDA (TTM)

RNAC0.00x

WHWK0.00x

Beta

RNAC0.74

WHWK0.99

52W Performance

RNAC-31.0%

WHWK65.3%

YTD Performance

RNAC4.4%

WHWK44.3%

% from 52W High

RNAC-35.9%

WHWK-35.9%

% from 52W Low

RNAC26.0%

WHWK88.2%

Asset Turnover (TTM)

RNAC0.01x

WHWK0.23x

FCF Yield (TTM)

RNAC-37.9%

WHWK-36.6%

Earnings Yield (TTM)

RNAC-74.3%

WHWK-42.2%

Dividend Yield (TTM)

RNACN/A

WHWKN/A

Rule of 40

RNAC-5,343.1

WHWK-100.0

EV/GP/RG

RNACN/A

WHWKN/A

Ticker research

View RNAC research View WHWK research

Metric	RNAC Cartesian Therapeutics Inc	WHWK Whitehawk Therapeutics Inc
Market & Valuation
Market Cap	$207M	$189M
Enterprise Value	$113M	$104M
Price	$7.06	$3.52
P/E Ratio	N/A	N/A
P/S Ratio	140.34x	7.56x
EV/Sales	76.18x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	296.12x	1.15x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.43x	-1.50x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	473.62x	N/A
Revenue & Growth
Revenue (TTM)	$1M	$0
Revenue Growth (YoY)	-20.7%	-100.0%
Forward Rev Growth	-14.0%	167.6%
Profitability
Gross Margin (TTM)	0.0%	88.7%
Operating Margin (TTM)	0.0%	87.4%
EBITDA Margin (TTM)	-6503.1%	0.0%
Net Margin (TTM)	-10422.5%	99.4%
FCF Margin (TTM)	-5322.4%	N/A
Net Income (TTM)	$-154M	$-80M
FCF (TTM)	$-79M	$-69M
EPS (TTM)	-$5.16	-$0.96
ROE (TTM)	-321582.0%	-5389.0%
ROA (TTM)	-4761.0%	-4997.0%
ROIC (TTM)	-321582.0%	-5389.0%
Financial Health
Cash	$148M	$85M
Debt	$53M	$0
Net Cash/Debt	$95M	$85M
Current Ratio (TTM)	7.48x	17.38x
Quick Ratio (TTM)	7.19x	17.16x
Debt/Equity (TTM)	0.28x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.74	0.99
52W Performance	-31.0%	65.3%
YTD Performance	4.4%	44.3%
% from 52W High	-35.9%	-35.9%
% from 52W Low	26.0%	88.2%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.23x
FCF Yield (TTM)	-37.9%	-36.6%
Earnings Yield (TTM)	-74.3%	-42.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-5,343.1	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View RNAC research	View WHWK research